Intra-Cellular Therapies: Number of Employees 2013-2022 | ITCI
Interactive chart of Intra-Cellular Therapies (ITCI) annual worldwide employee count from 2013 to 2022.
- Intra-Cellular Therapies total number of employees in 2021 was 512, a 33.68% increase from 2020.
- Intra-Cellular Therapies total number of employees in 2020 was 383, a 16.06% increase from 2019.
- Intra-Cellular Therapies total number of employees in 2019 was 330, a 352.05% increase from 2018.
- Intra-Cellular Therapies total number of employees in 2018 was 73, a 48.98% increase from 2017.
| Intra-Cellular Therapies Annual Number of Employees | |
|---|---|
| 2021 | 512 |
| 2020 | 383 |
| 2019 | 330 |
| 2018 | 73 |
| 2017 | 49 |
| 2016 | 42 |
| 2015 | 39 |
| 2014 | 51 |
| 2013 | 22 |
| 2012 | 21 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $5.204B | $0.084B |
| Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $163.597B | 9.95 |
| Bio-Rad Laboratories (BIO.B) | United States | $14.907B | 32.33 |
| QIAGEN (QGEN) | Netherlands | $10.865B | 17.15 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.248B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.228B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.901B | 48.18 |
| Emergent Biosolutions (EBS) | United States | $1.599B | 6.85 |
| Myovant Sciences (MYOV) | United Kingdom | $1.236B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.320B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.114B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.104B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.103B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.087B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
